Ironwood pharmaceuticals, inc. (IRWD)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Revenues:
Total revenues

428,413

346,639

298,276

273,957

149,555

76,436

22,881

150,245

65,871

43,857

34,321

Cost and expenses:
Cost of revenues

23,875

32,751

19,097

1,868

12

5,291

7,203

965

-

-

-

Write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments

-3,530

247

309

374

17,638

20,292

-

-

-

-

-

Research and development

115,044

101,060

88,145

139,492

108,746

101,890

102,378

113,474

86,093

77,454

76,100

Selling, general and administrative

172,450

219,676

231,184

173,281

125,247

118,333

123,228

92,538

45,920

27,169

-

Amortization of acquired intangible assets

-

8,111

6,214

981

-

-

-

-

-

-

-

Gain on fair value remeasurement of contingent consideration

3,169

-31,045

-31,310

9,831

-

-

-

-

-

-

-

Restructuring expenses

3,600

14,700

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

151,800

-

-

-

-

-

-

-

-

-

Collaboration expense

-

-

-

-

-

-

42,074

16,030

-

-

-

Total cost and expenses

308,290

497,309

313,639

325,827

251,643

245,806

274,883

223,007

132,013

104,623

95,137

General and administrative

-

-

-

-

-

-

-

-

-

-

19,037

Income (loss) from operations

120,123

-150,670

-15,363

-51,870

-102,088

-169,370

-252,002

-72,762

-66,142

-60,766

-60,816

Other (expense) income:
Interest expense

36,602

37,724

36,370

39,153

31,096

21,166

21,002

59

63

196

318

Interest and investment income

2,862

2,991

2,111

1,169

443

257

192

197

456

614

240

(Loss) gain on derivatives

3,000

-8,700

-3,284

8,146

-9,928

-

-

-

-

-

-

Loss on extinguishment of debt

-31,000

-

-2,009

-

-

-

-

-

-

-

-

Remeasurement of forward purchase contracts

-

-

-

-

-

-

-

-

-

-

600

Other income

514

-

-

-

-

661

-

-

900

993

-

Other expense, net

-61,180

-43,476

-39,552

-29,838

-40,581

-20,248

-20,810

138

1,293

1,411

522

Net loss before income tax expense

-

-

-

-

-

-

-

-

-64,849

-59,355

-60,294

Income tax expense

-

-

-

-

-

-

-

-

3

-2,944

-296

Net income (loss) from continuing operations

58,943

-194,146

-54,915

-

-

-

-

-

-

-56,411

-59,998

Net loss from discontinued operations

-37,438

-88,222

-62,022

-

-

-

-

-

-

4,551

-13,314

Net income (loss) and comprehensive income

21,505

-282,368

-116,937

-81,708

-142,669

-189,618

-272,812

-72,624

-64,852

-52,981

-71,185

Net loss

-

-

-

-

-

-

-

-

-

-51,860

-73,312

Net income from discontinued operations attributable to noncontrolling interest

-

-

-

-

-

-

-

-

-

1,121

-2,127

Net income per share from continuing operations - basic and diluted (in dollars per share)

0.38

-1.27

-0.37

-

-

-

-

-

-

-0.63

-8.43

Net loss per share from discontinued operations - basic and diluted (in dollars per share)

-0.24

-0.58

-0.42

-

-

-

-

-

-

0.04

-1.57

Net income (loss) per share - basic and diluted (in dollars per share)

0.14

-1.85

-0.78

-0.56

-1.00

-1.39

-2.35

-0.68

-0.65

-0.59

-10.00

Weighted average common shares outstanding used in computing net income (loss) per share- basic and diluted:

156,023

152,634

148,993

144,928

142,155

136,811

115,852

106,403

99,875

89,653

-

Weighted average shares used in computing net income (loss) per share - basic

-

-

-

-

-

-

-

-

-

-

7,116

Weighted average shares used in computing net income (loss) per share - diluted

-

-

-

-

-

-

-

-

-

-

7,116

Collaborative arrangements revenue
Total revenues

379,652

272,839

265,533

263,923

149,040

-

-

-

-

-

-

Product revenue, net
Total revenues

-

3,445

3,061

109

-

-

-

-

-

-

-

Sale of active pharmaceutical ingredient
Total revenues

48,761

70,355

29,682

9,925

515

-

-

-

-

-

-